PODD Q1 Earnings Call: Insulet Highlights New Leadership and Strong Omnipod Adoption

Insulin delivery company Insulet Corporation (NASDAQ:PODD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 28.8% year on year to $569 million. On top of that, next quarter’s revenue guidance ($608.2 million at the midpoint) was surprisingly good and 5.5% above what analysts were expecting. Its non-GAAP profit of $1.02 per share was 29.7% above analysts’ consensus estimates.

Is now the time to buy PODD? Find out in our full research report (it’s free).

StockStory’s Take

Insulet’s first quarter results reflected continued momentum in automated insulin delivery, driven by robust demand for the Omnipod 5 platform across both U.S. and international markets. Management cited commercial execution, with CEO Ashley McEvoy emphasizing the company’s unique positioning at the intersection of consumer health and medical technology. The team pointed to growth in new customer starts for both type 1 and type 2 diabetes, with over 85% of U.S. new starts coming from multiple daily injection (MDI) users and more than 30% from type 2 patients. CFO Ana Chadwick highlighted operational improvements and manufacturing efficiencies, resulting in gross margin expansion and stable retention rates, especially following the launch of Omnipod 5 in new international markets.

Looking ahead, Insulet’s guidance for the next quarter and the full year is underpinned by ongoing investments in product innovation, expanded commercial reach, and international market launches. CEO Ashley McEvoy stated that the company’s priorities remain focused on advancing technology, driving growth in both type 1 and type 2 diabetes segments, and expanding Omnipod 5’s global footprint. She noted, “Our strategy is intact. We will continue to drive robust growth and do so profitably on a global scale.” Management also discussed the impacts of tariffs and supply chain dynamics, but expressed confidence in maintaining margin expansion through efficiency gains and scale. Omnipod 5 launches in new countries and continued direct-to-consumer marketing are expected to further support growth.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to strong Omnipod 5 adoption, commercial investments, and operational discipline across manufacturing and supply chain.

• Type 2 diabetes expansion: The U.S. launch of Omnipod 5 for type 2 diabetes contributed to over 30% of new customer starts in the quarter, supported by a recently expanded sales force and targeted direct-to-consumer advertising.
• International growth momentum: International markets saw Omnipod 5 launches in Canada and Switzerland, bringing the total to 13 countries, with further expansion planned in the Middle East. International new customer starts increased sequentially, driven by new sensor integrations and customer upgrades.
• Advances in automation and manufacturing: Investments in advanced automation and the ramp-up of the Malaysia facility were cited as key drivers of gross margin expansion. Management stated the Malaysia site is on track to be accretive to margins by the third quarter.
• Direct-to-consumer (DTC) strategy: Higher conversion rates from DTC efforts are bringing more interested patients into the Omnipod ecosystem. Management highlighted more efficient advertising spend and improved lead conversion.
• Stable retention and utilization: Retention rates remained steady in the U.S. and improved internationally with Omnipod 5 adoption. Utilization metrics for new type 2 users closely mirrored those for type 1, with only slightly higher attrition, as expected by management.

Drivers of Future Performance

Insulet expects continued growth, supported by Omnipod 5 adoption, expansion into new markets, and operational efficiencies, while monitoring potential risks from tariffs and international launches.

• Broader type 2 adoption: Management is prioritizing growth in the U.S. type 2 diabetes segment, focusing on expanding prescriber reach through a larger sales force and leveraging clinical data to promote adoption. Early results show increased prescription activity among health care providers, and management believes the market could double or triple in the coming years, though the exact pace remains uncertain.
• International market expansion: The company is launching Omnipod 5 in new regions, including recent entries into Canada and Switzerland and planned launches in the Middle East. Management expects international growth to be driven primarily by volume as more markets upgrade from earlier Omnipod versions, with ongoing efforts to adapt U.S. commercial strategies to fit international contexts.
• Margin management amid tariffs: Insulet forecasts stable gross and operating margins, despite a projected 50 basis point impact from tariffs related to China. Investments in automation and diversified manufacturing are expected to offset these pressures, and the company is raising its gross margin outlook while maintaining ongoing R&D and commercial investments.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) whether Insulet can maintain momentum in type 2 diabetes adoption and expanded health care provider engagement, (2) the progress and outcomes of new international Omnipod 5 launches—particularly in the Middle East, and (3) the impact of manufacturing scale-ups and automation on gross margins. Developments in direct-to-consumer strategies and tariff management will also be important markers of execution.

Insulet currently trades at a forward P/E ratio of 69.1×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High Quality Stocks for All Market Conditions

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.